Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models-Reference-Cited by-同舟云学术

Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models

Published:1999-12 Issue:12 Volume:38 Page:1831-1839
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Kłodzińska Aleksandra,Chojnacka-Wójcik Ewa,Pałucha Agnieszka,Brański Piotr,Popik Piotr,Pilc Andrzej

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference50 articles.

1. Evaluation of a rapid technique for detecting minor tranquilizers;Aron;Neuropharmacology,1971

2. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740;Bond;Neuroreport,1997

3. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice;Cappendijk;Eur. Neuropsychopharmacol.,1993

4. Anxiolytic-like effects of metabotropic glutamate antagonist (RS)-alpha-methylserine-O-phosphate in rats;Chojnacka-Wójcik;Polish J. Pharmacol.,1997

5. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats;Chojnacka-Wójcik;Eur. J. Pharmacol.,1997

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabotropic Glutamate Receptors in Anxiety Disorder;Anxiety and Anguish - Psychological Explorations and Anthropological Figures;2023-10-09

2. Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?;Expert Opinion on Pharmacotherapy;2021-06-23

3. Peripubertal mGluR2/3 Agonist Treatment Prevents Hippocampal Dysfunction and Dopamine System Hyperactivity in Adulthood in MAM Model of Schizophrenia;Schizophrenia Bulletin;2021-04-30

4. The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus;Neuropsychopharmacology;2020-07-14

5. Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations;Depression and Anxiety;2020-05-17